These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 38473371)

  • 21. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
    Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
    Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
    Seitz G; Warmann SW; Vokuhl CO; Heitmann H; Treuner C; Leuschner I; Fuchs J
    Pediatr Surg Int; 2007 May; 23(5):431-9. PubMed ID: 17211591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
    Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
    Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
    Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
    Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR
    Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Soft tissue sarcomas in children.
    Kapoor G; Das K
    Indian J Pediatr; 2012 Jul; 79(7):936-42. PubMed ID: 21935710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with completely resected nongenitourinary low-risk embryonal rhabdomyosarcoma are candidates for reduced duration low-intensity chemotherapy.
    Bisogno G; Fuchs J; Dasgupta R; Ferrari A; Haduong JH; Rogers T; Walterhouse DO; Coppadoro B; Xue W; Vokuhl C; Hawkins DS; Seitz G; Merks JHM; Sparber-Sauer M; Venkatramani R
    Cancer; 2022 Dec; 128(23):4150-4156. PubMed ID: 36250420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and Future Treatment Strategies for Rhabdomyosarcoma.
    Chen C; Dorado Garcia H; Scheer M; Henssen AG
    Front Oncol; 2019; 9():1458. PubMed ID: 31921698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy and prognostic significance of regional lymph node involvement in embryonal rhabdomyosarcoma: a report from the European paediatric Soft tissue sarcoma Study Group.
    Ben-Arush M; Minard-Colin V; Scarzello G; Fajardo RD; Terwisscha Van Scheltinga S; Bernier V; Jenney M; Gallego S; Zanetti I; Cesen M; Merks JHM; Bisogno G
    Eur J Cancer; 2022 Sep; 172():119-129. PubMed ID: 35763871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
    Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
    Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of synchronous chemoresistant pulmonary metastasis from pleomorphic rhabdomyosarcoma with stereotaxic body radiation therapy: A case report and a review of the literature.
    Benkhaled S; Mané M; Jungels C; Shumelinsky F; Aubain NS; Van Gestel D
    Cancer Treat Res Commun; 2021; 26():100282. PubMed ID: 33360328
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
    Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treating soft tissue sarcomas with adjuvant chemotherapy.
    Patrikidou A; Domont J; Cioffi A; Le Cesne A
    Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.
    Ruymann FB; Grovas AC
    Cancer Invest; 2000; 18(3):223-41. PubMed ID: 10754991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Embryonal rhabdomyosarcoma completely resected at diagnosis: The European paediatric Soft tissue sarcoma Study Group RMS2005 experience.
    Bergeron C; Jenney M; De Corti F; Gallego S; Merks H; Glosli H; Ferrari A; Ranchère-Vince D; De Salvo GL; Zanetti I; Chisholm J; Minard-Colin V; Rogers T; Bisogno G;
    Eur J Cancer; 2021 Mar; 146():21-29. PubMed ID: 33567392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials.
    Tramsen L; Bochennek K; Sparber-Sauer M; Salzmann-Manrique E; Scheer M; Dantonello T; Borkhardt A; Dirksen U; Thorwarth A; Greiner J; Ebinger M; Weclawek-Tompol J; Ladenstein R; Ljungman G; Hallmen E; Lehrnbecher T; Koscielniak E; Klingebiel T
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapamycin targeting mTOR and hedgehog signaling pathways blocks human rhabdomyosarcoma growth in xenograft murine model.
    Kaylani SZ; Xu J; Srivastava RK; Kopelovich L; Pressey JG; Athar M
    Biochem Biophys Res Commun; 2013 Jun; 435(4):557-61. PubMed ID: 23665330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome and prognostic variables in childhood rhabdomyosarcoma (RMS) with emphasis on impact of FOXO1 fusions in non-metastatic RMS: experience from a tertiary cancer centre in India.
    Ramanathan S; Sisodiya S; Shetty O; Prasad M; Parambil BC; Shah S; Ramadwar M; Khanna N; Laskar S; Qureshi S; Vora T; Chinnaswamy G
    Ecancermedicalscience; 2023; 17():1539. PubMed ID: 37138963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS; Bogart E; Casanova M; Merks JHM; Bisogno G; Calareso G; Gallego Melcon S; Gatz SA; Le Deley MC; McHugh K; Probst A; Rocourt N; van Rijn RR; Wheatley K; Minard-Colin V; Chisholm JC
    J Clin Oncol; 2021 Sep; 39(27):2979-2990. PubMed ID: 34343032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.